Search Press releases Keywords From To 8 Feb 2023 FINTEPLA[®]▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Read More 18 Jan 2023 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis Read More 9 Jan 2023 UCB's financial update Read More 6 Jan 2023 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Read More 23 Dec 2022 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab Read More 19 Dec 2022 FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Read More Pagination First page Previous page Previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
